18F-FDG PET Imaging in the Evaluation of Treatment Response to New Chemotherapies beyond Imatinib for Patients with Gastrointestinal Stromal Tumors

@inproceedings{Stefanelli2011,
  title={
					18F-FDG PET Imaging in the Evaluation of Treatment Response to New Chemotherapies beyond Imatinib for Patients with Gastrointestinal Stromal Tumors},
  author={Antonella Stefanelli and Giorgio Treglia and Paoletta Mirk and Barbara Muoio and Alessandro Giordano},
  booktitle={ISRN gastroenterology},
  year={2011}
}
Aim. (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) is a powerful tool for staging and defining "good responders" to chemotherapy in tumor setting. Gastrointestinal stromal tumors (GISTs) are sarcoma involving gastrointestinal tract and may require a chemotherapy including imatinib, a tyrosine kinase inhibitor agent. Some GIST patients become refractory to imatinib; therefore, other tyrosine kinase inhibitors or concomitant chemotherapy may be considered for treatment… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Gastrointestinal stromal tumors ( GISTs ) are sarcoma involving gastrointestinal tract and may require a chemotherapy including imatinib , a tyrosine kinase inhibitor agent .
18F - FDG PET Imaging in the Evaluation of Treatment Response to New Chemotherapies beyond Imatinib for Patients with Gastrointestinal Stromal Tumors
Gastrointestinal stromal tumors ( GISTs ) are sarcoma involving gastrointestinal tract and may require a chemotherapy including imatinib , a tyrosine kinase inhibitor agent .
Gastrointestinal stromal tumors ( GISTs ) are sarcoma involving gastrointestinal tract and may require a chemotherapy including imatinib , a tyrosine kinase inhibitor agent .
All Topics